Elevated tau‐PET signal predicts near‐term conversion to mild cognitive impairment in cognitively unimpaired older adults

National Institute on Aging‐Alzheimer’s Association workgroups have proposed biological research criteria to identify individuals with preclinical Alzheimer’s disease (AD). It remains unclear whether cognitively unimpaired individuals with abnormality in both amyloid (A) and tau (T) biomarkers will go on to develop a clinical AD syndrome. In two independent cohorts, we investigated whether elevated tau‐PET signal in persons with elevated amyloid‐PET predicts near‐term conversion to mild cognitive impairment (MCI). We also tested whether neurodegeneration (N), a non‐specific marker typical of later‐stage AD, improved such prediction.